Digg, Reddit, Propellor, Stumble and more
|
"Because of ethical concerns," the article
said, "the researchers did not randomly assign the women to either stop or
continue medication." Instead, the AP reported, the women decided what to do and then the "researchers watched what happened." But the actual report on the study shows that of the 201 participants, 13 miscarried, 5 terminated their pregnancy, 12 were lost to follow-up prior to the end of pregnancy, and 8 chose to withdraw from the study. So when reporting on the few pregnant women that remained, the study said mothers were 5 times more likely to suffer a relapse than those who continued taking the drugs. However, a highly relevant finding rarely mentioned, in what turned out to be this wee little study, is that 26% of the women who remained on the drugs became depressed anyways. The study authors noted that of the 82 women who continued antidepressant treatment throughout pregnancy, 21 or 26% relapsed. But there were only 65 women in the group that discontinued the drugs, so the results logically showed a higher rate of relapse when 45 became depressed. Moreover, nearly 2 years before the study was published in JAMA, on January 13, 2004, the lead author, Dr Lee Cohen was quoted in the New York Times as saying about 75 to 80% of pregnant women who go off antidepressants will relapse during the pregnancy. Six months after JAMA ran the study, the July 11, 2006 Wall Street Journal explained why the 13 "experts" might encourage pregnant women to keep taking SSRIs, in stating the lead author, Dr Cohen, who was a Harvard Medical School professor and director of the research program at Massachusetts General, was a longtime consultant to the 3 antidepressant makers, a paid speaker for 7, and his research work was funded by 4 drug companies. In fact, the Journal reported, "the study and resulting television and newspaper reports of the research failed to note that most of the 13 authors are paid as consultants or lecturers by the makers of antidepressants," and "the authors failed to disclose more than 60 different financial relationships with drug companies." And just like clock-work, the Cohen's study was widely cited in other journals promoting the sale of SSRIs to pregnant women. "In summary, it seems clear that the risks of not receiving adequate antidepressant treatment thus far outweigh the risks of adverse events, not only in infants but in mothers as well," wrote Dr Pierre Blier of the University of Ottawa in editorial in the Journal of Psychiatry and Neuroscience, 2006;31(4):226-8. "The population," he warned, "should therefore learn to fear the illness more than the antidepressant." But as it turns out, Dr Blier conflicting interests included among others, being a consultant with Lilly, Forest Labs, Janssen, Wyeth and Sanofi-Aventis, and a contract employee with Forest Labs. He was also in the speaker's bureau for Lilly, Forest Labs, and Wyeth, and received grant funding from Lilly, Forest Labs and Wyeth. The JAMA study, along with a brief note from Dr Cohen himself, was also featured in the Spring 2006 issue of Massachusetts General Hospital's Center for Women's Health Newsletter, in a publication that downplayed the risk of just about all the birth defects discovered in recent years including heart birth defects and the infant withdrawal syndrome. Since 1990, JAMA has required authors of studies to list all financial interests and has published the disclosures. In an online editorial in July 2006, JAMA editor, Dr Catherine DeAngelis announced her intention to enforce the policy in part by publicizing any author's failure to follow the rules and specifically noted that 3 consecutive nondisclosures involved authors from Harvard Medical School and included Dr Cohen's study.
On July 11, 2006, citing material promoting the
events, the Wall Street Journal reported that the Massachusetts General
psychiatry academy planned to conduct Continuing Medical Education seminars
in a dozen cities across the US, with Dr Cohen overseeing a segment on the
treatment of pregnant women with psychiatric disorders. Seroctin is the Natural Serotonin! Seroctin 375 mg per capsule with 120 capsules per bottle. $24.99 Bottle + $5.00 shipping Seroctin is the natural serotonin optimizer. Order Seroctin now... Click here to Order Seroctin
White Eagle Soaring: Dream Dancer of the 7th Fire
|
|
Dream-Catchers Home Dream-Catchers History Dream-Catchers Gallery Weaving a Dream-Catcher Order Dream-Catchers Mother Earth Drum Seventh Fire Prophecy-Protest-Principle History of the Little Shell Band of Ojibwe History of the Ojibways
The Kokopelli Project |
Native News of the Seventh Fire
|
Disclaimer: The statements on www.real-dream-catchers.com have not been evaluated by the FDA. These dream catchers are not intended to diagnose nor treat nor cure any disease or illness. Neither are dreamcatchers, the dream catcher, nor any dreamcatcher.